Payment overview · 2025
General Payments
$227.44
7 reported records · 4 companies
Healthcare provider profile · identity verified
Niraj J Shah, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BELLEVILLE, IL · NPI 1134440969
Verified facts
What the public records show
CMS Open Payments records show Niraj J Shah, M.D. received $227.44 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 58.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $132.31 | 58.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.04 | 26.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.40 | 9.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.69 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.44 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $132.31 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 135 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
135 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
302 | 67 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1036 | 340 |
| Amlodipine Besylate | Amlodipine Besylate | 687 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 498 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 493 | 148 |
| Gabapentin | Gabapentin | 487 | 126 |
| Lisinopril | Lisinopril | 454 | 153 |
| Omeprazole | Omeprazole | 445 | 140 |
| Furosemide | Furosemide | 400 | 141 |
| Metformin Hcl | Metformin Hcl | 368 | 128 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 359 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 123 |
| Losartan Potassium | Losartan Potassium | 345 | 112 |
| Trazodone Hcl | Trazodone Hcl | 325 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 115 |
| Ozempic | Semaglutide | 302 | 67 |
| Alendronate Sodium | Alendronate Sodium | 295 | 108 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 292 | 64 |
| Simvastatin | Simvastatin | 277 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 273 | 75 |
| Tramadol Hcl | Tramadol Hcl | 273 | 81 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 257 | 93 |
| Potassium Chloride | Potassium Chloride | 245 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 74 |
| Famotidine | Famotidine | 208 | 70 |
| Jardiance | Empagliflozin | 206 | 59 |
| Alprazolam | Alprazolam | 202 | 41 |
| Montelukast Sodium | Montelukast Sodium | 201 | 66 |
| Eliquis | Apixaban | 199 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 60 |
| Allopurinol | Allopurinol | 182 | 56 |
| Mounjaro | Tirzepatide | 160 | 42 |
| Methylprednisolone | Methylprednisolone | 153 | 124 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 50 |
| Carvedilol | Carvedilol | 150 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 43 |
| Linzess | Linaclotide | 135 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 49 |
| Sertraline Hcl | Sertraline Hcl | 132 | 42 |
| Topiramate | Topiramate | 126 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 38 |
| Pregabalin | Pregabalin | 123 | 37 |
| Atenolol | Atenolol | 122 | 44 |
| Meloxicam | Meloxicam | 121 | 42 |
| Bupropion Xl | Bupropion Hcl | 119 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 26 |
| Prednisone | Prednisone | 101 | 73 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 98 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 29 |
| Celecoxib | Celecoxib | 91 | 32 |
| Spironolactone | Spironolactone | 90 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 31 |
| Azithromycin | Azithromycin | 82 | 69 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 26 |
| Farxiga | Dapagliflozin Propanediol | 81 | 20 |
| Ezetimibe | Ezetimibe | 80 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 68 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 72 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 26 |
| Xarelto | Rivaroxaban | 71 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 23 |
| Bumetanide | Bumetanide | 67 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 18 |
| Trulicity | Dulaglutide | 65 | 20 |
| Buspirone Hcl | Buspirone Hcl | 63 | 20 |
| Metformin Hcl Er | Metformin Hcl | 63 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 24 |
| Finasteride | Finasteride | 60 | 21 |
| Januvia | Sitagliptin Phosphate | 59 | 17 |
| Naproxen | Naproxen | 58 | 24 |
| Mirtazapine | Mirtazapine | 57 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 45 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 50 | 18 |
| Lorazepam | Lorazepam | 49 | 22 |
| Sucralfate | Sucralfate | 49 | 27 |
| Clonazepam | Clonazepam | 47 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 18 |
| Clonidine Hcl | Clonidine Hcl | 46 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 28 |
| Glimepiride | Glimepiride | 42 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Rybelsus | Semaglutide | 41 | 12 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Ondansetron Odt | Ondansetron | 39 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 14 |
| Synthroid | Levothyroxine Sodium | 39 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 15 |
| Valacyclovir | Valacyclovir Hcl | 38 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 12 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 16 |
| Meclizine Hcl | Meclizine Hcl | 35 | 17 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | 13 |
| Baclofen | Baclofen | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | 12 |
| Carisoprodol | Carisoprodol | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 13 |
| Aripiprazole | Aripiprazole | 28 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Valsartan | Valsartan | 25 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Nystatin | Nystatin | 20 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 17 |
| Ramipril | Ramipril | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Tobramycin | Tobramycin | 16 | 11 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Prolia | Denosumab | 15 | 13 |
| Risperidone | Risperidone | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.44 · 7 records | Novo Nordisk Inc | CREON, LINZESS, NURTEC ODT, QULIPTA, Veozah, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error